The global centrifugal blood pumps market size was valued at USD 63.0 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 5.4% from 2021 to 2028. Market participants are progressively focusing on developing advanced centrifugal blood pumps to meet the demands of healthcare professionals is the factor expected to augment market growth. The increasing prevalence of cardiac disorders along with steadily growing indications for heart transplantation is anticipated to accelerate the demand for centrifugal blood pumps. An increasing number of cardiovascular complications in COVID-19 recovered patients is expected to boost the demand for blood pumps in upcoming years.
Mechanical cardiac assist devices such as centrifugal blood pumps have achieved widespread acceptance for the treatment of cardiac insufficiency. Their prime task is to maintain blood circulation and provide sufficient oxygen supply to body tissue and organs if the natural heart is failing. Cardiac fibrillation or cardiogenic shock requires efficient means of cardiac support. For such purposes, continuous centrifugal blood pumps are used. Rising cases of cardiac-related disorders including cardiac fibrillation are expected to favor the market growth. As per the CDC, coronary heart disease is among the most common type of heart disease, and around 365,914 people died in 2017 due to this. Also, as per the WHO, about 17.9 million people die of cardiovascular disorders each year. Hence, the increasing prevalence of cardiovascular diseases globally is anticipated to boost the market growth.
Several manufacturers are focusing on developing technologically advanced centrifugal blood pumps to maintain a strong market presence. Companies are modifying their product indications for COVID-19 treatment. For instance, In June 2020, Medtronic made artificial lung therapy for COVID-19 affected patients. As per new FDA guidance, Medtronic’s Affinity centrifugal blood pumps can be used for more than 6 hours in the ECMO circuit to treat people having cardiopulmonary failure during the COVID-19 pandemic.
Centrifugal pumps offer the advantage of decreased trauma to red blood cells and a less pronounced systemic inflammatory response compared with roller pumps. Centrifugal pumps and roller pumps are used in ECLS. Both techniques have theoretical advantages in terms of biocompatibility and complications. Roller pumps may induce high arterial pressure levels, leading to negative venous pressure levels and disruption of connections with the risk of endothelial damage in cannulated veins. These complications highlight the need for thorough pressure monitoring and regulation. Centrifugal pumps act through a spinning rotor to generate blood flow. This technique avoids high pressures in the case of distal circuit occlusion, fostering the market growth.
The electronic segment accounted for the largest revenue share of 73.5% in 2020. Electronic centrifugal blood pumps offer advantages such as energy conservation and process optimization that permit centrifugal blood pump systems to reduce the expense of cardiopulmonary bypass surgeries. Electronic centrifugal blood pumps offer the advantage of less pronounced systemic inflammatory response and decreased trauma to red blood cells compared to roller pumps, enhancing segment growth.
The mechanical segment is expected to expand at a CAGR of 4.3% over the forecast period. Mechanical centrifugal blood pumps are widely used in circulatory assist procedures and conventional adult cardiopulmonary bypass procedures, fostering segment growth. However, due to technological advancements demand mechanical centrifugal pumps increases, thereby limiting the demand for mechanical centrifugal pumps.
The hospitals segment dominated the market and captured the highest revenue share of 38.2% in 2020. The presence of advanced healthcare facilities and a skilled workforce providing a superior and wide range of cardiac treatment is expected to fuel the segmental growth. An increasing number of patient admissions in hospitals suffering from cardiac disorders is also anticipated to fuel market growth.
Growing awareness of ambulatory care centers especially in the U.S., Europe, and SEA countries are expected to fuel the growth of the ambulatory surgery centers segment. The segment is expected to grow fast during the forecast period. The segment is inclusive of ambulatory surgery, ambulatory care for patients, and organ transport systems. Rising investments for expanding ASC business and supporting reimbursement policies are expected to boost segment growth from 2021 to 2028.
North America dominated the market and accounted for the largest revenue share of 39.9% in 2020. Rising R&D expenditure, increasing prevalence of cardiovascular disorders, and rising initiatives by key market players in developing advanced centrifugal blood pumps in the U.S. and Canada are factors that contributed to North America’s leading market share in 2020. The presence of technologically advanced healthcare infrastructure is predicted to foster the number of treatments leading to surged demand for centrifugal pumps. The increasing occurrence of cardiovascular disorders across the U.S. and Canada is anticipated to create demand for centrifugal blood pumps for ECMO, ventricular assistance, and cardiopulmonary bypass.
In Asia Pacific, the centrifugal blood pumps market is projected to grow at the fastest rate of 6.2% during the forecast period. The rising focus on making advanced treatment accessible and improvements in healthcare policies in emerging countries such as India and Japan are anticipated to fuel the regional growth. Emerging economies are experiencing a rising number of advanced interventional cardiac procedures, leading to a surging adoption rate of centrifugal blood pumps. Additionally, the rising adoption of cardiac assist devices for cardiopulmonary bypass is estimated to accelerate regional growth.
In Europe, the market is expected to witness a lucrative growth rate of 4.9% during the forecast period. Improved healthcare infrastructure services and a rising number of research activities specifically for cardiovascular disorders are expected to contribute to the region’s market growth. An increasing number of products receiving CE approval is expected to drive the market demand among hospitals, ambulatory surgical centers, and others. For instance, in December 2019, QuraSrl’s Quantum centrifugal blood pump received CE approval.
Product launch, regulatory product approvals, strategic acquisitions, and innovation are major strategies adopted by the market players to retain their market share. Some of the prominent players in the centrifugal blood pumps market include:
Medtronic
LivaNovaplc
Qura srl
Abbott Laboratories
Terumo Corporation
Braille Biomedica Ltd.
Getinge AB
3M
Baxter International
Report Attribute |
Details |
Market size value in 2021 |
USD 87.9 million |
Revenue forecast in 2028 |
USD 126.7 million |
Growth Rate |
CAGR of 5.4% from 2021 to 2028 |
Base year for estimation |
2020 |
Historical data |
2016 - 2019 |
Forecast period |
2021 - 2028 |
Quantitative units |
Revenue in USD million and CAGR from 2021 to 2028 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Type, end use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; India; Japan; China; Australia; South Korea; Brazil; Mexico; Argentina; Colombia; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Medtronic; Getinge AB; Terumo Corporation; LivaNovaPlc; Abbott Laboratories; Qura Srl; Braille Biomedica Ltd; 3M; Baxter International |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional, and segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global centrifugal blood pumps market report on the basis of type, end use, and region:
Type Outlook (Revenue, USD Million, 2016 - 2028)
Electronic
Mechanical
End-use Outlook (Revenue, USD Million, 2016 - 2028)
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others
Regional Outlook (Revenue, USD Million, 2016 - 2028)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Asia Pacific
China
Japan
India
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
b. The hospital segment dominated the centrifugal blood pumps market and captured the highest revenue share of 38.2% in 2020.
b. North America dominated the centrifugal blood pumps market and accounted for the largest revenue share of 39.9% in 2020.
b. The global centrifugal blood pumps market size was estimated at USD 63.0 million in 2020 and is expected to reach USD 87.9 million in 2021.
b. The global centrifugal blood pumps market is expected to grow at a compound annual growth rate of 5.4% from 2021 to 2028 to reach USD 126.7 million by 2028.
b. The electronic segment accounted for the largest revenue share of 73.5% in 2020 in the centrifugal blood pumps market.
b. Some key players operating in the centrifugal blood pumps market include Medtronic, LivaNova plc., Qura srl, Abbott Laboratories, Terumo Corporation, Braille Biomedica Ltd., Getinge AB, and 3M.
b. Key factors that are driving the centrifugal blood pumps market growth include the increasing prevalence of cardiac disorders, technological advancements, and an increasing number of heart transplantation procedures.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."